Phaseline

Companies › Energenesis Biomedical

Energenesis Biomedical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ENERGI-F703 GEL
Not specified
–Phase 3Diabetic Foot Ulcer–
ENERGI-F703EB Cream–Phase 2Epidermolysis Bullosa (EB)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05930210ENERGI-F703 GELPhase 3Diabetic Foot UlcerMetabolic and endocrineDec 2025
NCT07858422ENERGI-F703EB CreamPhase 2Epidermolysis Bullosa (EB)OtherMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biotechnology Institute IMASD BrightGene Bio-Medical Technology Soleno Therapeutics Beijing QL Biopharmaceutical CSPC Zhongnuo Pharmaceutical (Shijiazhuang)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.